Alcon AG（ALC）の株式分析ALCAlcon AG

Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries. It operates in the Healthcare sector.

Alcon AG (ALC) is a good buy right now, trading at $70.17 with a forward P/E of 16.23, indicating reasonable valuation compared to its growth prospects. The recent acquisition of Neurotech for $550 million enhances its product portfolio, which could drive future revenue growth. Additionally, the stock has shown a 5-day change of +6.03%, suggesting positive momentum. However, a key risk is the declining net income reported for Q2 2026, which was $0, indicating potential challenges ahead.